GHENT, Belgium, 18 November 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced its business update, summarising the non-audited financial position for the first nine months of 2015, material events since 30 September 2015 and the outlook for the next period.
Operating highlights – third quarter 2015
• Significant expansion of the immuno-oncology collaboration with Merck & Co., Inc., (known as MSD outside the United States and Canada) which now includes 17 programmes, with a focus on multi-specific Nanobodies® directed towards immune modulator targets.
Help employers find you! Check out all the jobs and post your resume.
